Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.

The awards will be handed out at a gala event scheduled for October 9 at New York City’s Cipriani Wall Street.

A webcast and a conference call for analysts, investors and media representatives will be held on Friday, 18 July 2025 at 13.30 EEST. A link to the live webcast is available on Orion's website at ...

Closing of the Merger Expected in Early August DUBLIN, July 17, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that the Irish High Court has given the necessary ruling to enable ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...

There is limited research on chronic pelvic pain in men, which delays treatment for male patients experiencing symptoms of ...

US biotech Crinetics Pharmaceuticals (Nasdaq: CRNX) has released new data on its investigational oral therapy Palsonify (paltusotine), supporting its potential as a convenient alternative to monthly ...

Amylyx Pharmaceuticals drew increased retail attention late Sunday after new clinical data presented at ENDO 2025 highlighted the potential of its lead candidate, avexitide, to significantly reduce ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATH ...

Endometriosis is as common as diabetes and asthma, yet in Ireland it takes eight to 10 years to get diagnosed on average. It ...